The role of virus-specific adoptive T-cell therapy in hematopoietic transplantation

References

• Gratwohl A, Brand R, Frassoni F, Rocha V, Niederwieser D, Reusser P, . Cause of death after allogeneic haematopoietic stem cell transplantation (HSCT) in early leukaemias: an EBMT analysis of lethal infectious complications and changes over calendar time. Bone Marrow Transplant. 2005;36:757–69.
   PubMed Web of Science ®Google Scholar
• Reusser P, Riddell SR, Meyers JD, Greenberg PD. Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease. Blood. 1991;78:1373–80.
   PubMed Web of Science ®Google Scholar
• Peggs KS, Verfuerth S, Pizzey A, Chow SL, Thomson K, Mackinnon S. Cytomegalovirus-specific T cell immunotherapy promotes restoration of durable functional antiviral immunity following allogeneic stem cell transplantation. Clin Infect Dis. 2009;49:1851–60.
   PubMed Web of Science ®Google Scholar
• Peggs KS. Adoptive T cell immunotherapy for cytomegalovirus. Expert Opin Biol Ther. 2009;9:725–36.
   PubMed Web of Science ®Google Scholar
• Leen AM, Sili U, Bollard CM, Rooney CM. Adoptive immunotherapy for herpesviruses. In: Arvin A, Campadelli-Fiume G, Mocarski E, Moore PS, Roizman B, Whitley R, . Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis. Cambridge University Press, Chapter 74, pages 1318–1331.
   Google Scholar
• Fujita Y, Rooney CM, Heslop HE. Adoptive cellular immunotherapy for viral diseases. Bone Marrow Transplant. 2008;41:193–8.
   PubMed Web of Science ®Google Scholar
• Einsele H, Ehninger G, Hebart H, Wittkowski KM, Schuler U, Jahn G, . Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation. Blood. 1995;86:2815–20.
   PubMed Web of Science ®Google Scholar
• Einsele H, Hebart H, Kauffmann-Schneider C, Sinzger C, Jahn G, Bader P, . Risk factors for treatment failures in patients receiving PCR-based preemptive therapy for CMV infection. Bone Marrow Transplant. 2000;25:757–63.
   PubMed Web of Science ®Google Scholar
• Mori T, Okamoto S, Matsuoka S, Yajima T, Wakui M, Watanabe R, . Risk-adapted pre-emptive therapy for cytomegalovirus disease in patients undergoing allogeneic bone marrow transplantation. Bone Marrow Transplant. 2000;25:765–9.
   PubMed Web of Science ®Google Scholar
• Keenan RD, Ainsworth J, Khan N, Bruton R, Cobbold M, Assenmacher M, . Purification of cytomegalovirus-specific CD8 T cells from peripheral blood using HLA-peptide tetramers. Br J Haematol. 2001;115:428–34.
   PubMed Web of Science ®Google Scholar
• Neudorfer J, Schmidt B, Huster KM, Anderl F, Schiemann M, Holzapfel G, . Reversible HLA multimers (streptamers) for the isolation of human cytotoxic T lymphocytes functionally active against tumor- and virus-derived antigens. J Immunol Methods. 2007;320:119–31.
   PubMed Web of Science ®Google Scholar
• Knabel M, Franz TJ, Schiemann M, Wulf A, Villmow B, Schmidt B, . Reversible MHC multimer staining for functional isolation of T-cell populations and effective adoptive transfer. Nat Med. 2002;8:631–7.
   PubMed Web of Science ®Google Scholar
• Assenmacher M, Lohning M, Radbruch A. Detection and isolation of cytokine secreting cells using the cytometric cytokine secretion assay. Curr Protoc Immunol. 2002;Chapter 6:Unit 6 27.
   Google Scholar
• Cobbold M, Khan N, Pourgheysari B, Tauro S, McDonald D, Osman H, . Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers. J Exp Med. 2005;202:379–86.
   PubMed Web of Science ®Google Scholar
• Yao J, Bechter C, Wiesneth M, Harter G, Gotz M, Germeroth L, . Multimer staining of cytomegalovirus phosphoprotein 65-specific T cells for diagnosis and therapeutic purposes: a comparative study. Clin Infect Dis. 2008;46:96–105.
   PubMed Web of Science ®Google Scholar
• Schmitt A, Tonn T, Busch DH, Grigoleit GU, Einsele H, Odendahl M, . Adoptive transfer and selective reconstitution of streptamer-selected cytomegalovirus-specific CD8 + T cells leads to virus clearance in patients after allogeneic peripheral blood stem cell transplantation. Transfusion. 2011;51:591–9.
   PubMed Web of Science ®Google Scholar
• Feuchtinger T, Opherk K, Bethge WA, Topp MS, Schuster FR, Weissinger EM, . Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation. Blood. 2010;116:4360–7.
   PubMed Web of Science ®Google Scholar
• Peggs KS, Thomson K, Samuel E, Dyer G, Armoogum J, Chakraverty R, . Directly selected cytomegalovirus-reactive donor T cells confer rapid and safe systemic reconstitution of virus-specific immunity following stem cell transplantation. Clin Infect Dis. 2011;52:49–57.
   PubMed Web of Science ®Google Scholar
• Sylwester AW, Mitchell BL, Edgar JB, Taormina C, Pelte C, Ruchti F, . Broadly targeted human cytomegalovirus-specific CD4 + and CD8 + T cells dominate the memory compartments of exposed subjects. J Exp Med. 2005;202:673–85.
   PubMed Web of Science ®Google Scholar
• Zandvliet ML, van Liempt E, Jedema I, Veltrop-Duits LA, Willemze R, Guchelaar HJ, . Co-ordinated isolation of CD8(+) and CD4(+) T cells recognizing a broad repertoire of cytomegalovirus pp65 and IE1 epitopes for highly specific adoptive immunotherapy. Cytotherapy. 2010;12:933–44.
   PubMed Web of Science ®Google Scholar
• Landgren O, Gilbert ES, Rizzo JD, Socie G, Banks PM, Sobocinski KA, . Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation. Blood. 2009;113:4992–5001.
   PubMed Web of Science ®Google Scholar
• Styczynski J, Einsele H, Gil L, Ljungman P. Outcome of treatment of Epstein–Barr virus-related post-transplant lymphoproliferative disorder in hematopoietic stem cell recipients: a comprehensive review of reported cases. Transpl Infect Dis. 2009;11:383–92.
   PubMed Web of Science ®Google Scholar
• Heslop HE, Slobod KS, Pule MA, Hale GA, Rousseau A, Smith CA, . Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood. 2010;115:925–35.
   PubMed Web of Science ®Google Scholar
• Uhlin M, Okas M, Gertow J, Uzunel M, Brismar TB, Mattsson J. A novel haplo-identical adoptive CTL therapy as a treatment for EBV-associated lymphoma after stem cell transplantation. Cancer Immunol Immunother. 2010;59:473–7.
   PubMed Web of Science ®Google Scholar
• Moosmann A, Bigalke I, Tischer J, Schirrmann L, Kasten J, Tippmer S, . Effective and long-term control of EBV PTLD after transfer of peptide-selected T cells. Blood. 2010;115:2960–70.
   PubMed Web of Science ®Google Scholar
• Heemskerk B, Lankester AC, van Vreeswijk T, Beersma MF, Claas EC, Veltrop-Duits LA, . Immune reconstitution and clearance of human adenovirus viremia in pediatric stem-cell recipients. J Infect Dis. 2005;191:520–30.
   PubMed Web of Science ®Google Scholar
• Feuchtinger T, Lucke J, Hamprecht K, Richard C, Handgretinger R, Schumm M, . Detection of adenovirus-specific T cells in children with adenovirus infection after allogeneic stem cell transplantation. Br J Haematol. 2005;128:503–9.
   PubMed Web of Science ®Google Scholar
• Chakrabarti S, Mautner V, Osman H, Collingham KE, Fegan CD, Klapper PE, . Adenovirus infections following allogeneic stem cell transplantation: incidence and outcome in relation to graft manipulation, immunosuppression, and immune recovery. Blood. 2002;100:1619–27.
   PubMed Web of Science ®Google Scholar
• Molinier-Frenkel V, Lengagne R, Gaden F, Hong SS, Choppin J, Gahery-Segard H, . Adenovirus hexon protein is a potent adjuvant for activation of a cellular immune response. J Virol. 2002;76:127–35.
   PubMed Web of Science ®Google Scholar
• Feuchtinger T, Lang P, Hamprecht K, Schumm M, Greil J, Jahn G, . Isolation and expansion of human adenovirus-specific CD4 + and CD8 + T cells according to IFN-gamma secretion for adjuvant immunotherapy. Exp Hematol. 2004;32:282–9.
   PubMed Web of Science ®Google Scholar
• Feuchtinger T, Richard C, Joachim S, Scheible MH, Schumm M, Hamprecht K, . Clinical grade generation of hexon-specific T cells for adoptive T-cell transfer as a treatment of adenovirus infection after allogeneic stem cell transplantation. J Immunother. 2008;31:199–206.
   PubMed Web of Science ®Google Scholar
• Chatziandreou I, Gilmour KC, McNicol AM, Costabile M, Sinclair J, Cubitt D, . Capture and generation of adenovirus specific T cells for adoptive immunotherapy. Br J Haematol. 2007;136:117–26.
   Google Scholar
• Aissi-Rothe L, Decot V, Venard V, Jeulin H, Salmon A, Clement L, . Rapid generation of full clinical-grade human antiadenovirus cytotoxic T cells for adoptive immunotherapy. J Immunother. 2010;33:414–24.
   Google Scholar
• Feuchtinger T, Matthes-Martin S, Richard C, Lion T, Fuhrer M, Hamprecht K, . Safe adoptive transfer of virus-specific T-cell immunity for the treatment of systemic adenovirus infection after allogeneic stem cell transplantation. Br J Haematol. 2006;134:64–76.
   PubMed Web of Science ®Google Scholar
• O'Donnell PH, Swanson K, Josephson MA, Artz AS, Parsad SD, Ramaprasad C, . BK virus infection is associated with hematuria and renal impairment in recipients of allogeneic hematopoietic stem cell transplants. Biol Blood Marrow Transplant. 2009;15:1038–48.
   PubMed Web of Science ®Google Scholar
• Hirsch HH, Knowles W, Dickenmann M, Passweg J, Klimkait T, Mihatsch MJ, . Prospective study of polyomavirus type BK replication and nephropathy in renal-transplant recipients. N Engl J Med. 2002;347:488–96.
   PubMed Web of Science ®Google Scholar
• Hardinger KL, Koch MJ, Bohl DJ, Storch GA, Brennan DC. BK-virus and the impact of pre-emptive immunosuppression reduction: 5-year results. Am J Transplant. 2010;10:407–15.
   PubMed Web of Science ®Google Scholar
• Harkensee C, Vasdev N, Gennery AR, Willetts IE, Taylor C. Prevention and management of BK-virus associated haemorrhagic cystitis in children following haematopoietic stem cell transplantation: a systematic review and evidence-based guidance for clinical management. Br J Haematol. 2008;142:717–31.
   PubMed Web of Science ®Google Scholar
• Blyth E, Clancy L, Simms R, Gaundar S, O'Connell P, Micklethwaite K, . BK virus-specific T cells for use in cellular therapy show specificity to multiple antigens and polyfunctional cytokine responses. Transplantation. 2011;92:1077–84.
   Google Scholar
• Comoli P, Basso S, Azzi A, Moretta A, De Santis R, Del Galdo F, . Dendritic cells pulsed with polyomavirus BK antigen induce ex vivo polyoma BK virus-specific cytotoxic T-cell lines in seropositive healthy individuals and renal transplant recipients. J Am Soc Nephrol. 2003;14:3197–204.
   Google Scholar
• Schmidt-Hieber M, Schwender J, Heinz WJ, Zabelina T, Kuhl JS, Mousset S, . Viral encephalitis after allogeneic stem cell transplantation: a rare complication with distinct characteristics of different causative agents. Haematologica. 2011;96:142–9.
   Google Scholar
• Kharfan-Dabaja MA, Ayala E, Greene J, Rojiani A, Murtagh FR, Anasetti C. Two cases of progressive multifocal leukoencephalopathy after allogeneic hematopoietic cell transplantation and a review of the literature. Bone Marrow Transplant. 2007;39:101–7.
   PubMed Web of Science ®Google Scholar
• Kraemer C, Evers S, Nolting T, Arendt G, Husstedt IW. Cidofovir in combination with HAART and survival in AIDS-associated progressive multifocal leukoencephalopathy. J Neurol. 2008;255:526–31.
   PubMed Web of Science ®Google Scholar
• Khanna N, Wolbers M, Mueller NJ, Garzoni C, Du Pasquier RA, Fux CA, . JC virus-specific immune responses in human immunodeficiency virus type 1 patients with progressive multifocal leukoencephalopathy. J Virol. 2009;83:4404–11.
   PubMed Web of Science ®Google Scholar
• Balduzzi A, Lucchini G, Hirsch HH, Basso S, Cioni M, Rovelli A, . Polyomavirus JC-targeted T-cell therapy for progressive multiple leukoencephalopathy in a hematopoietic cell transplantation recipient. Bone Marrow Transplant. 2011;46:987–92.
   PubMed Web of Science ®Google Scholar
• Leen AM, Myers GD, Sili U, Huls MH, Weiss H, Leung KS, . Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med. 2006;12:1160–6.
   PubMed Web of Science ®Google Scholar
• Gerdemann U, Vera JF, Rooney CM, Leen AM. Generation of multivirus-specific T cells to prevent/treat viral infections after allogeneic hematopoietic stem cell transplant. J Vis Exp. 2011;51:2736.
   Google Scholar
• Zandvliet ML, van Liempt E, Jedema I, Kruithof S, Kester MG, Guchelaar HJ, . Simultaneous isolation of CD8(+) and CD4(+) T cells specific for multiple viruses for broad antiviral immune reconstitution after allogeneic stem cell transplantation. J Immunother. 2011;34:307–19.
   PubMedGoogle Scholar
• Lugthart G, Albon SJ, Ricciardelli I, Kester MG, Meij P, Lankester AC, . Simultaneous generation of multivirus-specific and regulatory T cells for adoptive immunotherapy. J Immunother. 2012;35:42–53.
   PubMed Web of Science ®Google Scholar
• Khanna N, Stuehler C, Conrad B, Lurati S, Krappmann S, Einsele H, . Generation of a multipathogen-specific T-cell product for adoptive immunotherapy based on activation-dependent expression of CD154. Blood. 2011;118:1121–31.
   PubMed Web of Science ®Google Scholar
• Haque T, Wilkie GM, Jones MM, Higgins CD, Urquhart G, Wingate P, . Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. Blood. 2007;110:1123–31.
   PubMed Web of Science ®Google Scholar
• Qasim W, Derniame S, Gilmour K, Chiesa R, Weber M, Adams S, . Third-party virus-specific T cells eradicate adenoviraemia but trigger bystander graft-versus-host disease. Br J Haematol. 2011;154:150–3.
   PubMed Web of Science ®Google Scholar
• Hanley PJ, Cruz CR, Savoldo B, Leen AM, Stanojevic M, Khalil M, . Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes. Blood. 2009;114:1958–67.
   PubMed Web of Science ®Google Scholar
• Hanley PJ, Martinez C, Leung K, Savaldo B, Dotti G, Gee AP, . Phase I study to improve virus-specific immune reconstitution after cord blood transplantation using cord blood-derived virus-specific cytotoxic T lymphocytes. ASH Ann Meet Abstr. 2011;118:155.
   Google Scholar
• Schub A, Schuster IG, Hammerschmidt W, Moosmann A. CMV-specific TCR-transgenic T cells for immunotherapy. J Immunol. 2009;183:6819–30.
   PubMed Web of Science ®Google Scholar
• Bendle GM, Linnemann C, Hooijkaas AI, Bies L, de Witte MA, Jorritsma A, . Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy. Nat Med. 2010;16:565–70.
   PubMed Web of Science ®Google Scholar
• Full F, Lehner M, Thonn V, Goetz G, Scholz B, Kaufmann KB, . T cells engineered with a cytomegalovirus-specific chimeric immunoreceptor. J Virol. 2010;84:4083–8.
   PubMed Web of Science ®Google Scholar